If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 222.00
Bid: 221.50
Ask: 222.50
Change: -1.00 (-0.45%)
Spread: 1.00 (0.451%)
Open: 220.00
High: 224.00
Low: 220.00
Prev. Close: 223.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

Fri, 17th Nov 2023 07:58

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

UK retail sales declined last month despite expectations of a month-on-month increase, and declined faster than expected on an annual basis, official numbers on Friday showed.

"Cost of living pressures, reduced footfall and the great British weather all played their part. There are signs that cracks are starting to appear in the economy with consumers tightening their belts and switching to cheaper brands. Consumers are still spending more and getting less with retail sales volumes now at their lowest level since February 2021," said Wealth Club's Charlie Huggins.

Meanwhile, Swissquote Bank analyst Ipek Ozkardeskaya was upbeat ahead of the final day of trading this week, particularly when reflecting upon the week's news coming out of the US.

"This week could hardly be better in terms of economic, political, and geopolitical news. The US inflation slowed more than expected, the US politicians inked a short-term deal to avert a shutdown," said Ozkardeskaya.

"On top, the US retail sales fell last month, but fell less than expected, the initial jobless claims rose, and the US unemployment benefits reached the highest level in almost two years, factory production fell more than expected and homebuilder sentiment fell to the lowest level for the year."

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up 0.4% at 7,441.17

----------

Hang Seng: down 2.1% at 17,452.71

Nikkei 225: closed up 0.5% at 33,585.20

S&P/ASX 200: closed down 0.1% at 7,049.40

----------

DJIA: closed down 45.74 points, or 0.1%, at 34,945.47

S&P 500: closed up 5.36 points, or 0.1%, at 4,508.24

Nasdaq Composite: closed up 9.84 points, or 0.1%, at 14,113.67

----------

EUR: down at USD1.0839 (USD1.0840)

GBP: down at USD1.2377 (USD1.2398)

USD: down at JPY150.50 (JPY151.34)

Gold: up at USD1,986.42 per ounce (USD1,966.26)

(Brent): down at USD77.41 a barrel (USD80.84)

(changes since previous London equities close)

----------

ECONOMICS

----------

Friday's key economic events still to come:

10:00 CET EU balance of payments

11:00 CET EU CPI

08:30 EST US housing starts

08:30 CST US Fed Chicago President Austan Goolsbee speaks

10:00 EST US advance quarterly services

US FRB Boston President Susan Collins speaks

US Federal Reserve Board Vice Chair Michael Barr speaks

UK BoE Deputy Governor David Ramsden speaks

----------

According to the Office for National Statistics, retail sales volumes declined 2.7% year-on-year in October, quickening from a 1.3% decline in September. The September figure was revised from a previous 1.0% decline. The October read also came in worse than feared, with market expectations of a 1.5% decline, according to FXStreet-cited consensus. Retail sales declined 0.3% in October from September, falling short of consensus. A monthly increase of 0.3% was forecast, according to FXStreet. In September, retail sales had fallen 1.1% from August, revised from a previous 0.9% decline. "Non-food stores sales volumes fell by 0.2% in October 2023, following a 2.1% fall in September 2023; retailers suggested that cost of living, reduced footfall and the wet weather in the second half of the month contributed to the fall," the ONS noted.

----------

US President Joe Biden has signed a temporary spending bill a day before a potential government shutdown. The move pushes a fight with congressional Republicans over the federal budget into the new year, and wartime aid for Ukraine and Israel remains stalled. The measure passed the US house and senate by wide bipartisan margins this week, ensuring the government remains open until after the holiday season. It also potentially giving legislators more time to sort out their considerable differences over government spending levels for the current fiscal year. Biden signed the bill in San Francisco, where he is hosting the summit of Asia-Pacific Economic Co-operation economies.

----------

BROKER RATING CHANGES

----------

Barclays raises NatWest to 'overweight' (equal weight) - price target 330 (315) pence

----------

Barclays raises Babcock International to 'overweight' (equal weight) - price target 529 (325) pence

----------

Jefferies cuts Great Portland Estates to 'underperform' (hold) - price target 352 (387) pence

----------

COMPANIES - FTSE 100

----------

AstraZeneca said its Truqap treatment for patients with advanced hormone receptor positive breast cancer, in combination with Faslodex, has been approved by the US Food & Drug Administration. This follows the results from its CapItello-291 phase 3 trial published earlier this year, which showed reduced risk of disease progression or death by 50% compared to Faslodex alone. AstraZeneca Executive Vice President, Oncology Business Unit Dave Fredrickson commented: "The rapid US approval of Truqap reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test patients at the time of diagnosis, as up to fifty per cent have tumours with these alterations. As a first-in-class medicine, this approval provides a critical new option for patients in the US with this specific type of disease and we look forward to bringing Truqap to the many breast cancer patients who can benefit across the globe."

----------

COMPANIES - FTSE 250

----------

PureTech Health said its founded entity Karuna Therapeutics has announced positive results from its phase 1b ambulatory blood pressure monitoring trial of KarXT in treating schizophrenia. The biotechnology firm said results demonstrate that KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia. This is alongside meeting its primary endpoint of demonstrating a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of negative 0.59 millimetres of mercury. It said KarXT was "generally well tolerated", with a side effect profile consistent with prior trials in the Emergent programme evaluating KarXT in schizophrenia.

----------

OTHER COMPANIES

----------

FRP Advisory said its performance was strong during the half-year that ended October 31. The corporate finance, restructuring and debt adviser said it expects first half revenue of GBP58.7 million, up 19% from GBP49.4 million a year earlier, alongside underlying adjusted earnings before interest, tax, depreciation and amortisation rising 34% to GBP15.5 million from GBP11.6 million. It noted the restructuring having seen an increase in activity levels during calendar 2023, including administrations approaching pre-pandemic levels. The company said: "Companies with significant borrowings who have rolled off lower interest rate arrangements are now subject to much higher debt service costs, with interest rates now considerably higher than the 2009-2021 period...Certain sectors such as construction, property, casual dining and food service, retail, administrative and support services are finding current trading conditions particularly challenging." Chief Executive Officer Geoff Rowley added: "We remain confident of making further progress, with leading positions in our core markets and a team and structure that leaves us well positioned to support corporates through the business cycle and respond to increased demand for our services."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
27 Feb 2024 11:28

PureTech notes positive results from Shionogi's EndeavorRx ADHD trial

(Alliance News) - PureTech Health PLC on Tuesday noted that its founded entity, Akili Inc, has announced positive results from a phase 3 clinical trial of EndeavorRx for children with attention deficit hyperactivity disorder in Japan.

Read more
20 Dec 2023 09:53

PureTech makes strong progress, expects "multiple catalysts" next year

(Alliance News) - PureTech Health PLC on Wednesday said it made "strong strategic and clinical progress" in 2023, and predicted "a productive and exciting" tear to come.

Read more
1 Dec 2023 14:29

TRADING UPDATES: N4 launches investor hub; Capricorn production falls

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:

Read more
17 Nov 2023 09:44

IN BRIEF: PureTech hails schizophrenia trial results for Karuna drug

PureTech Health PLC - Boston, Massachusetts-based FTSE 250 biotechnology company - Founded entity Karuna Therapeutics reports "positive results" from Phase 1b trial evaluating the effects of xanomeline-trospium, brand name KarXT, on 24-hour ambulatory blood pressure in adults with schizophrenia. Karuna says KarXT does not cause clinically meaningful blood pressure increases, with an average change from baseline at week eight of minus 0.59 mmHg or millimetre of mercury. Other vital signs like average diastolic blood pressure and heart rate were consistent with previous KarXT trials in schizophrenia. Adds that KarXT was generally well-tolerated, and side effects remained consistent with prior trials under the Emergent programme. Karuna in late September announced its application to the US Food & Drug Administration for approval of KarXT to treat schizophrenia; if successful, it will be PureTech's third therapeutic candidate to gain FDA approval. KarXT is also in development to treat psychosis associated with Alzheimer's disease.

Read more
14 Nov 2023 10:59

PureTech Health celebrates positive results in Phase 2 anxiety trial

(Alliance News) - PureTech Health PLC on Tuesday said its therapeutic LYT-300 achieved its primary endpoint for acute anxiety reduction, in a Phase 2a trial using healthy volunteers.

Read more
11 Oct 2023 14:22

IN BRIEF: PureTech's LYT-100 shows 50% improvement to key adverse events

PureTech Health PLC - Boston-based biotechnology company - Says LYT-100 trial shows around 50% improvement in gastrointestinal and central nervous system related adverse events in adults suffering from idiopathic pulmonary fibrosis compared to US Food & Drug Administration-approved pirfenidone. Adds data shows higher dose of LYT-100 well-tolerated with no additional incidence of GI or CNS AEs when titrated up from 550 milligrams dosage.

Read more
4 Oct 2023 13:55

PureTech Health subsidiary receives fast track designation for VE202

(Alliance News) - PureTech Health PLC on Wednesday said its subsidiary Vedanta Biosciences has received fast-track designation for its VE202 treatment.

Read more
28 Sep 2023 15:08

TRADING UPDATES: Rockhopper loss widens; Synectics inks new contract

(Alliance News) - (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
27 Sep 2023 10:40

Arix Bioscience boosts net value, CEO jumping ship for PureTech Health

(Alliance News) - Arix Bioscience PLC on Wednesday said net asset value increased in its latest half year, but has since launched a strategic review due to "unfavourable" conditions while Chief Executive Officer Robert Lyne prepares to step down.

Read more
29 Aug 2023 09:39

PureTech narrows interim loss despite "stormy market challenges"

(Alliance News) - PureTech Health PLC on Tuesday said its half-year loss narrowed, but saw its revenue fall by more than half.

Read more
29 Aug 2023 09:03

LONDON MARKET OPEN: FTSE 100 catches up with bank holiday rally

(Alliance News) - Stock prices in London opened higher on Tuesday, as UK markets return from a long bank holiday weekend and news that UK shop price inflation decelerated in August.

Read more
29 Aug 2023 07:49

LONDON BRIEFING: Bunzl profit up; Rio Tinto sells copper project stake

(Alliance News) - Stocks in London are called to open higher on Tuesday, following a long bank holiday weekend.

Read more
22 Aug 2023 15:46

UK earnings, trading statements calendar - next 7 days

Wednesday 23 August 
Angling Direct PLCTrading Statement
Costain Group PLCHalf Year Results
Thursday 24 August 
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
James Cropper PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Princess Private Equity Holding LtdHalf Year Results
Redcentric PLCFull Year Results
South32 LtdFull Year Results
Tribal Group PLCHalf Year Results
Friday 25 August 
no events scheduled 
Monday 28 August 
no events scheduled 
Tuesday 29 August 
Amaroq Minerals LtdHalf Year Results
Bunzl PLCHalf Year Results
Dalata Hotel Group PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
PureTech Health PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Aug 2023 17:31

TRADING UPDATES: Plant Health in Poland boost; PureTech gets US grant

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.